Skip to content

LBRX LBRX Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

Septerna, Inc. logo
Septerna, Inc.SEPN
$0-100%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$47.16M
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+163%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: LBRX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's net proceeds from sales of subsidiary shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's net proceeds from sales of subsidiary shares?
LBRX (LBRX) reported net proceeds from sales of subsidiary shares of $81.94M in Q4 2025.
What does net proceeds from sales of subsidiary shares mean?
Represents the gross cash inflows generated from the company's initial public offering of equity securities. This metric is a primary indicator of the capital raised to fund long-term growth, research and development, or general corporate purposes during the transition to a public entity.